Metastatic Colorectal Cancer

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed the importance of biomarker testing and the challenges involved.

CHICAGO — The addition of panitumumab vs. bevacizumab to standard doublet chemotherapy significantly extended survival among patients with RAS wild-type and left-sided metastatic colorectal cancer, according to study results.

Many physicians in private practices and S corporations are overlooking a simple tax reduction tactic, according to experts.

More than 70% of patients with metastatic colorectal cancer bore financial hardships within the first year of diagnosis despite most having health insurance, according to study results published in Journal of the National Cancer Institute.

March is Colorectal Cancer Awareness Month.

Celyad Oncology placed a voluntary pause on a clinical trial of CYAD-101 after two patients treated with the investigational chimeric antigen receptor T-cell therapy died.

Weight loss during the first 3 months of systemic therapy for metastatic colorectal cancer coincided with significantly shorter OS compared with stable or increasing weight, according to study results.

First-line nivolumab plus standard of care chemotherapy failed to prolong 1-year PFS among patients with metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Younger and older patients with metastatic colorectal cancer had similar survival outcomes despite differences in fitness levels and treatment intensity, according to study results published in Journal of the National Cancer Institute.